Diamond Therapeutics begins study on very low doses of psilocybin

Diamond Therapeutics contracts BioPharma Services for Phase 1 clinical trial

While there have been few studies on microdosing psilocybin, Diamond Therapeutics Inc.’s preclinical research suggests that very low, non-hallucinogenic doses of psilocybin have potential for treating disorders like anxiety and depression. Diamond is now partnering with BioPharma Services Inc. to expand on this research in a new phase 1 clinical trial, which will explore a range of very low doses of psilocybin.

PDF of article